November 18, 2026
Health news, explained with evidence
LIVE

Re-Evaluating Implantable Cardioverter-Defibrillators for Patients With Higher LVEF Levels

❤️ Conditions & Care 1 min read 👁 1

Recent medical insights discuss the limitations of current left ventricular ejection fraction thresholds used for implantable cardioverter-defibrillator therapy.

❤️Conditions & Care

Key points

  • ICDs are standard therapy for primary prevention of sudden cardiac death
  • Current guidelines use an LVEF cutoff of 35 percent or less
  • Most sudden cardiac arrest victims lack significant left ventricular dysfunction

Understanding Current Cardiac Device Guidelines

The implantable cardioverter-defibrillator, commonly known as an ICD, continues to serve as a fundamental treatment for preventing sudden cardiac death. Established randomized clinical trials have previously confirmed a clear survival advantage for primary prevention using ICDs in patients presenting with a left ventricular ejection fraction of 35 percent or lower. Consequently, current professional medical guidelines rely heavily on this specific threshold to determine device eligibility.

Despite these established criteria, clinical data indicates that the majority of people who suffer a sudden cardiac arrest actually do not exhibit significant left ventricular dysfunction. Medical experts note that these ejection fraction cutoffs are largely arbitrary, and the underlying risk of sudden cardiac arrest does not strictly follow a simple binary division. As a result, researchers continue to study how patient selection methods might be refined.

What to know: While ICD guidelines provide a standard framework for high-risk cardiac patients, medical thresholds are continuously evolving as new evidence emerges. Readers should consult a qualified healthcare provider for personalized medical advice regarding cardiac devices and treatment decisions.

Source JAMA Network — jamanetwork.com/journals/jama/fullarticle/2853396 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.